Everand Logo

Welcome to Everand!

  • STAT

    At a big cardiology meeting, glitzy tech will collide with sober science

    It’s rare that we get actual hard data on whether a new technology we are inviting into our lives is a good idea. But we're about to get some.
    by Matthew Herper Mar 14, 2019 3 minutes
    Jeff Williams, Apple's chief operating officer, speaks about the Apple Watch, at the product launch in September.

    We carry Star-Trek-style pocket computers, and worry that “screen time” is rotting our children’s brains. We know we’re living in the future. But it’s rare that we get actual hard data on whether a new technology we are inviting into our lives is a good idea.

    Such an opportunity will come Saturday, when we’ll learn more about the and its ability to detect serious heart conditions such as atrial fibrillation. Researchers from Stanford will present the results of

    You’re reading a preview, subscribe to read more.

    More from STAT

    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About MDMA For PTSD, A CRISPR Treatment For Blindness, And More
    An FDA advisory panel will deliberate on June 4 whether to recommend approval for the first MDMA-assisted therapy for post-traumatic stress disorder.
    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About MorphoSys Drug Risks, An AstraZeneca Admission, And More
    MorphoSys is dealing with a safety issue with pelabresib, the experimental treatment for myelofibrosis and centerpiece of its proposed $3 billion acquisition by Novartis.
    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About An Amgen Obesity Drug, A Senate Bill On Shortages, And More
    Amgen will no longer develop an early-stage obesity pill, and will instead focus on a more advanced injectable candidate to compete with Wegovy and Zepbound.

    Related